RESUMO
[ABSTRACT]. The COVID-19 pandemic has exacerbated social, economic, and health-related disparities, which disproportionately affect persons living in conditions of vulnerability. Such populations include ethnic groups who face discrimination and experience barriers to accessing comprehensive health care. The COVID-19 pandemic has exposed these health disparities, and disruptions of essential health services have further widened the gaps in access to health care. Noncommunicable diseases are more prevalent among groups most impacted by poor social determinants of health and have been associated with an increased likelihood of severe COVID-19 disease and higher mortality. Disruptions in the provision of essential health services for noncommunicable diseases, mental health, communicable diseases such as HIV, tuberculosis, and malaria, and maternal and child health services (including sexual and reproductive health), are projected to also increase poor health outcomes. Other challenges have been an increased frequency of interpersonal violence and food insecurity. Countries in the Americas have responded to the disruptions caused by the pandemic by means of health service delivery through telemedicine and other digital solutions and stepping up social service support interventions. As vaccinations for COVID-19 create the opportunity to overcome the pandemic, countries must strengthen primary health care and essential health services with a view to ensuring equity, if the region is to achieve universal health coverage in fulfillment of the Sustainable Development Goals.
[RESUMEN]. La pandemia de COVID-19 ha acentuado las desigualdades sociales, económicas y relacionadas con la salud, que afectan desproporcionadamente a las personas en situación de vulnerabilidad. Esta población incluye grupos étnicos que se enfrentan a la discriminación y obstáculos para el acceso a la atención integral de salud. La pandemia de COVID-19 ha expuesto estas desigualdades de salud, y las interrupciones de los servicios esenciales de salud han ampliado aún más las brechas en el acceso a la atención de salud. Las enfermedades no transmisibles son más prevalentes en los grupos que han sufrido un mayor impacto de los determinantes sociales de la salud deficientes y se han asociado con una mayor probabilidad de presentar un cuadro grave de COVID-19 y una mayor mortalidad. Asimismo, se proyecta que las interrupciones en la prestación de servicios esenciales de salud para las enfermedades no transmisibles, la salud mental, las enfermedades transmisibles como la infección por el VIH, la tuberculosis y la malaria, y los servicios de salud maternoinfantil (como la salud sexual y reproductiva) incrementen los resultados deficientes en materia de salud. Otros retos son una mayor frecuencia de la violencia interpersonal y la inseguridad alimentaria. Los países de la Región de las Américas han respondido a las interrupciones causadas por la pandemia con la prestación de servicios de salud mediante la telemedicina y otras soluciones digitales, y la aceleración de las intervenciones de apoyo de los servicios sociales. A medida que la vacunación contra la COVID-19 crea la oportunidad de superar la pandemia, los países deben fortalecer su atención primaria de salud y sus servicios de salud esenciales a fin de garantizar la equidad, para que la Región logre la cobertura universal de salud en cumplimiento de los Objetivos de Desarrollo Sostenible.
[RESUMO]. A pandemia de COVID-19 exacerbou as disparidades sociais, econômicas e as relacionadas à saúde, que afetam de maneira desproporcional as pessoas que vivem em situação de vulnerabilidade. Essas populações incluem grupos étnicos que enfrentam discriminação e barreiras para o acesso à atenção integral à saúde. A pandemia de COVID-19 expôs essas disparidades, e as interrupções nos serviços essenciais de saúde ampliaram ainda mais as lacunas no acesso aos cuidados de saúde. As doenças não transmissíveis são mais prevalentes entre os grupos mais afetados por determinantes sociais da saúde deficientes e estão associadas a um aumento na probabilidade de doença grave pela COVID-19 e mortalidade mais elevada. Prevê-se que as interrupções na prestação de serviços essenciais de saúde para doenças não transmissíveis, saúde mental, doenças transmissíveis como HIV, tuberculose e malária, bem como dos serviços de saúde materno-infantil (incluindo saúde sexual e reprodutiva) também aumentem os desfechos adversos de saúde. Outros desafios são o aumento da frequência da violência interpessoal e insegurança alimentar. Os países das Américas responderam às interrupções causadas pela pandemia com a prestação de serviços de saúde por meio da telemedicina e outras soluções digitais, e a aceleração de intervenções de apoio dos serviços sociais. À medida em que a vacinação contra a COVID-19 oferece a oportunidade de superar a pandemia, os países devem fortalecer a atenção primária à saúde e os serviços essenciais de saúde com o objetivo de garantir a equidade, para que a região atinja a cobertura universal de saúde em cumprimento aos Objetivos de Desenvolvimento Sustentável.
Assuntos
Disparidades nos Níveis de Saúde , Acesso Efetivo aos Serviços de Saúde , COVID-19 , Doenças não Transmissíveis , Fatores de Risco , Determinantes Sociais da Saúde , América , Disparidades nos Níveis de Saúde , Acesso Efetivo aos Serviços de Saúde , Doenças não Transmissíveis , Fatores de Risco , Determinantes Sociais da Saúde , América , Disparidades nos Níveis de Saúde , Acesso Efetivo aos Serviços de Saúde , Doenças não Transmissíveis , Fatores de Risco , Determinantes Sociais da Saúde , AméricaRESUMO
[RESUMEN]. Objetivo. Determinar el comportamiento de los indicadores de incidencia de tuberculosis (TB) y número de muertes por TB en el marco de la meta 3.3 de los Objetivos de Desarrollo Sostenible (ODS) y su correlación con los determinantes sociales. Métodos. Se utilizó una metodología de estudio ecológico, en el cual la unidad de análisis es la población. Para el análisis de los determinantes sociales, se hizo uso del modelo de regresión binomial negativo y la fuerza de asociación. Resultados. En las Américas se ha presentado una disminución promedio anual en la tasa de incidencia de TB de 0,3% entre 2009 y 2018; sin embargo, de 2015 a 2018 ha habido un aumento, pasando de 27,6 a 28,8 por 100 000 habitantes. Con respecto a los determinantes sociales, los grupos de países con índice de desarrollo humano (IDH) y producto interno bruto (PIB) más bajos tienen una incidencia de TB más alta. El riesgo de TB en el país con IDH más bajo es seis veces mayor que en el país con IDH más alto. Conclusiones. Al ritmo de la disminución actual de la tasa de incidencia y del número de muertes por TB, la Región de las Américas no alcanzará las metas propuestas en los ODS y en la Estrategia Fin de la TB. Se requiere una implementación y expansión rápidas de las intervenciones en prevención y control de TB para lograrlo. Esto implica, entre otras acciones, reducir las barreras de acceso al diagnóstico y tratamiento y fortalecer las iniciativas para abordar los determinantes sociales.
[ABSTRACT]. Objective. Determine patterns of tuberculosis (TB) incidence indicators and number of deaths from TB within the framework of target 3.3 of the Sustainable Development Goals (SDGs) and their correlation with social determinants. Methods. Ecological study methodology was used, in which the population is the unit of analysis. Social determinants were analyzed using a negative binomial regression model and strength of association. Results. In the Americas, there was an average annual reduction in the TB incidence rate of 0.3% from 2009 to 2018; however, from 2015 to 2018, the rate increased, from 27.6 to 28.8 per 100,000 population. With regard to social determinants, the groups of countries with the lowest human development index (HDI) and gross domestic product (GDP) have a higher incidence of TB. TB risk in the country with the lowest HDI is six times that of the country with the highest HDI. Conclusions. At the current rate of reduction in the incidence rate and number of deaths from TB, the Region of the Americas will not meet the targets in the SDGs and in the End TB Strategy. Rapid implementation and expansion of interventions for TB prevention and control are required to attain the targets. This involves, among other actions, reducing access barriers to diagnosis and treatment and strengthening initiatives to address social determinants.
[RESUMO]. Objetivo. Determinar o comportamento dos indicadores de incidência da tuberculose (TB) e o número de mortes por TB no quadro da meta 3.3 dos Objetivos de Desenvolvimento Sustentável (ODS) e sua correlação com os determinantes sociais. Métodos. Utilizamos uma metodologia de estudo ecológico, na qual a unidade de análise é a população. Para a análise dos determinantes sociais, utilizamos o modelo de regressão binomial negativo e a avaliamos a força das associações. Resultados. Nas Américas, observou-se uma redução anual média na taxa de incidência de TB de 0,3% entre 2009 e 2018; entretanto, de 2015 a 2018 houve um aumento, de 27,6 para 28,8 por 100.000 habitantes. Com relação aos determinantes sociais, os grupos de países com índice de desenvolvimento humano (IDH) e produto interno bruto (PIB) mais baixos apresentam uma maior incidência de TB. O risco de TB no país com o menor IDH é seis vezes maior que no país com o maior IDH. Conclusões. Se mantido o ritmo atual de redução na taxa de incidência e no número de mortes por TB, a Região das Américas não alcançará as metas propostas nos ODS e na Estratégia pelo Fim da Tuberculose. É necessária uma implementação e expansão mais rápida das intervenções de prevenção e controle da TB para alcançar este objetivo. Isto implica, entre outras ações, reduzir as barreiras de acesso ao diagnóstico e tratamento e fortalecer as iniciativas que abordam os determinantes sociais.
Assuntos
Tuberculose , Desenvolvimento Sustentável , Incidência , Determinantes Sociais da Saúde , Desenvolvimento Sustentável , Incidência , Determinantes Sociais da Saúde , Tuberculose , Desenvolvimento Sustentável , Incidência , Determinantes Sociais da SaúdeRESUMO
INTRODUCTION: Systematic reviews show that women living with HIV (WLHIV) have high unmet sexual and reproductive health (SRH) needs due to barriers to access sexual and reproductive health services (SRHS). In Latin America and the Caribbean (LAC), as of 2016, there were nearly one million WLHIV, but the existing evidence of their SRH needs comes from a few individual studies. This systematic review provides an overview of these women's needs to help define new and/or adapt existing public health strategies to the local context. This review synthesizes the evidence from the literature on the use of and access to SRHS related to family planning, antenatal care, abortion services and violence against WLHIV in LAC. METHODS: Using a systematic review of mixed studies, a search was performed in MEDLINE, EMBASE, LILACS, INASP, POPLINE, SCOPUS, for studies conducted in LAC, from 2004 to 2017, as well as contact with authors and hand search as needed. Two independent reviewers evaluated the quality of the studies using the Mixed Methods Appraisal Tool; inclusion was conducted according to the PRISMA flow diagram. An exploratory narrative synthesis followed by quantitative synthesis data was undertaken. Group analysis or meta-analysis was not considered appropriate given the level of heterogeneity of the studies. RESULTS: A total of 18 studies in 13 LAC countries for a population of 5672 WLHIV were included. Data from individual studies reported unmet family planning needs; higher, but inconsistent use of condom as the sole contraceptive method OR=1.46 [1.26 to 1.69]; lesser use of other non-permanent contraceptive methods OR=0.26 [0.22 to 0.31]; more unplanned pregnancies OR=1.30 [1.02 to 1.66]; more induced abortions OR=1.96 [1.60 to 2.39]; higher risk of immediate postpartum sterilization; and higher exposure to sexual and institutional violence by WLHIV when compared with women without HIV. CONCLUSIONS: This review presents evidence from LAC about the SRH unmet needs of WLHIV that must be addressed by decreasing institutional and structural barriers, facilitating services and reducing stigma, and discrimination among healthcare providers to improve access to SRHS based on human rights, so women independently of their HIV status can make their own reproductive decisions, free of violence and coercion.
Assuntos
Infecções por HIV/psicologia , Acessibilidade aos Serviços de Saúde , Adulto , Região do Caribe/epidemiologia , Anticoncepção , Feminino , Infecções por HIV/epidemiologia , Infecções por HIV/fisiopatologia , Infecções por HIV/prevenção & controle , Direitos Humanos , Humanos , América Latina/epidemiologia , Gravidez , Serviços de Saúde Reprodutiva , Estigma Social , Violência , Adulto JovemRESUMO
INTRODUCTION: HIV testing is the entry point for the elimination of mother-to-child transmission of HIV. Decreasing external funding for the HIV response in some low- and middle-income countries has triggered the question of whether a focused approach to HIV testing targeting pregnant women in high-burden areas should be considered. This study aimed at determining and comparing the cost-effectiveness of universal and focused HIV testing approaches for pregnant women across high to very low HIV prevalence settings. METHODS: We conducted a modelling analysis on health and cost outcomes of HIV testing for pregnant women using four country-based case scenarios (Namibia, Kenya, Haiti and Viet Nam) to illustrate high, intermediate, low and very low HIV prevalence settings. We used subnational prevalence data to divide each country into high-, medium- and low-burden areas, and modelled different antenatal and testing coverage in each. RESULTS: When HIV testing services were only focused in high-burden areas within a country, mother-to-child transmission rates remained high ranging from 18 to 23%, resulting in a 25 to 69% increase in new paediatric HIV infections and increased future treatment costs for children. Universal HIV testing was found to be dominant (i.e. more QALYs gained with less cost) compared to focused approaches in the Namibia, Kenya and Haiti scenarios. The universal approach was also very cost-effective compared to focused approaches, with $ 125 per quality-adjusted life years gained in the Viet Nam-based scenario of very low HIV prevalence. Sensitivity analysis further supported the findings. CONCLUSIONS: Universal approach to antenatal HIV testing achieves the best health outcomes and is cost-saving or cost-effective in the long term across the range of HIV prevalence settings. It is further a prerequisite for quality maternal and child healthcare and for the elimination of mother-to-child transmission of HIV.
Assuntos
Infecções por HIV/diagnóstico , Complicações Infecciosas na Gravidez/diagnóstico , Diagnóstico Pré-Natal/economia , Sorodiagnóstico da AIDS , Adolescente , Adulto , Análise Custo-Benefício , Feminino , Infecções por HIV/economia , Infecções por HIV/epidemiologia , Haiti , Humanos , Transmissão Vertical de Doenças Infecciosas/economia , Quênia , Programas de Rastreamento/economia , Pessoa de Meia-Idade , Namíbia , Gravidez , Complicações Infecciosas na Gravidez/epidemiologia , Prevalência , Anos de Vida Ajustados por Qualidade de Vida , Vietnã , Adulto JovemRESUMO
The world has pledged within the Sustainable Development Goals to end the AIDS epidemic by 2030. In Latin America and the Caribbean in 2015 approximately 2.0 million people were living with HIV and an estimated 100 000 new infections occurred. Yet, significant progress has been made in the Region of the Americas over the past ten years in expanding access and coverage of HIV care and treatment and in achieving elimination of mother-to-child transmission of HIV and syphilis (1, 2). Regarding HIV prevention, and HIV stigma and discrimination new regional elimination targets have also been developed and endorsed (3). However, challenges still persist; among them, a 3% increase in the rate of new HIV infections in the Region between 2010 and 2015 (4). This special issue on HIV/AIDS prevention, care and treatment in the Region of the Americas: achievements, challenges and perspectives provides an opportunity to present the current response to HIV/AIDS in the Region with a focus on three main areas: HIV prevention, HIV care and treatment, and the elimination of mother-to-child transmission of HIV and congenital syphilis. A call for papers was issued in early 2016, and 12 articles were selected for publication—nine original research papers, one brief communication, one review, and one opinion and analysis article. The papers represent seven different countries as well as an overview of the Caribbean sub-region. A successful HIV prevention program requires a combination of structural, biomedical, and behavioral interventions that are mutually reinforcing, continually evaluated, and tailored to the needs and risks of specific key populations and others who are vulnerable to infection. Previous reports have shown the importance of combination prevention strategies (5). The special issue addresses this by focusing on HIV prevention strategies available for men who have sex with men in the United States (6), as well as the social vulnerability of transgender persons (7). Both papers highlight the need for tailored interventions that take into account local epidemiological contexts....
Assuntos
HIV , Desenvolvimento Sustentável , Síndrome da Imunodeficiência Adquirida , Síndrome da Imunodeficiência AdquiridaAssuntos
Saúde Global/normas , Infecções por HIV/transmissão , Implementação de Plano de Saúde/métodos , Transmissão Vertical de Doenças Infecciosas/prevenção & controle , Complicações Infecciosas na Gravidez/prevenção & controle , Sífilis Congênita/transmissão , Cuba , Erradicação de Doenças , Feminino , Humanos , GravidezRESUMO
BACKGROUND: Access to highly active antiretroviral therapy (HAART) is expanding in Latin America. Many patients require second and third line therapy due to toxicity, tolerability, failure, or a combination of factors. The need for third line HAART, essential for program planning, is not known. METHODS: Antiretroviral-naïve patients ≥18 years who started first HAART after January 1, 2000 in Caribbean, Central and South America Network (CCASAnet) sites in Argentina, Brazil, Honduras, Mexico, and Peru were included. Clinical trials participants were excluded. Third line HAART was defined as use of darunavir, tipranavir, etravirine, enfuvirtide, maraviroc or raltegravir. Need for third line HAART was defined as virologic failure while on second line HAART. RESULTS: Of 5853 HAART initiators followed for a median of 3.5 years, 310 (5.3%) failed a second line regimen and 44 (0.8%) received a third line regimen. Cumulative incidence of failing a 2nd or starting a 3rd line regimen was 2.7% and 6.0% three and five years after HAART initiation, respectively. Predictors at HAART initiation for failing a second or starting a third line included female sex (hazard ratio [HR]â=â1.54, 95% confidence interval [CI] 1.18-2.00, pâ=â0.001), younger age (HRâ=â2.76 for 20 vs. 40 years, 95% CI 1.86-4.10, p<0.001), and prior AIDS (HRâ=â2.17, 95% CI 1.62-2.90, p<0.001). CONCLUSIONS: Third line regimens may be needed for at least 6% of patients in Latin America within 5 years of starting HAART, a substantial proportion given the large numbers of patients on HAART in the region. Improved accessibility to third line regimens is warranted.
Assuntos
Fármacos Anti-HIV/uso terapêutico , Terapia Antirretroviral de Alta Atividade , Infecções por HIV/tratamento farmacológico , Avaliação das Necessidades , Adulto , Feminino , Infecções por HIV/prevenção & controle , Humanos , América Latina , MasculinoAssuntos
Humanos , Atos Internacionais/prevenção & controle , Atos Internacionais/políticas , Formulação de Políticas , Terapia Antirretroviral de Alta Atividade/estatística & dados numéricos , Organização Pan-Americana da Saúde , Políticas, Planejamento e Administração em Saúde/organização & administraçãoAssuntos
Humanos , Atos Internacionais/prevenção & controle , Atos Internacionais/políticas , Formulação de Políticas , Terapia Antirretroviral de Alta Atividade/estatística & dados numéricos , Organização Pan-Americana da Saúde , Políticas, Planejamento e Administração em Saúde/organização & administraçãoRESUMO
A key component of the World Health Organization's (WHO's) Global HIV Drug Resistance (HIVDR) prevention and assessment strategy is to monitor HIVDR early-warning indicators (EWIs), which provide strategic information for HIVDR containment. The Pan American Health Organization (PAHO)/WHO supported implementation of HIVDR EWI monitoring in 16 Caribbean countries. Results from 15 countries were analyzed by year of patient initiation of antiretroviral therapy for the period 2005-2009. This report demonstrates the need for capacity-building to standardize prescribing practices and to strengthen adherence strategies and antiretroviral drug procurement management systems.
Assuntos
Antirretrovirais/farmacologia , Infecções por HIV/epidemiologia , Antirretrovirais/provisão & distribuição , Antirretrovirais/uso terapêutico , Região do Caribe/epidemiologia , Atenção à Saúde , Farmacorresistência Viral , Infecções por HIV/tratamento farmacológico , Indicadores Básicos de Saúde , Humanos , Perda de Seguimento , Adesão à Medicação , Cooperação do Paciente/estatística & dados numéricos , Vigilância da População , Organização Mundial da SaúdeRESUMO
By the end of 2010, Latin America and the Caribbean (LAC) achieved 63% antiretroviral treatment (ART) coverage. Measures to control HIV drug resistance (HIVDR) at the countrylevel are recommended to maximize the efficacy and sustainability of ART programs. Since 2006, the Pan American Health Organization has supported implementation of the WorldHealth Organization (WHO) strategy for HIVDR prevention and assessment through regional capacity-building activities and direct technical cooperation in 30 LAC countries. By 2010, 85 sites in 19 countries reported early warning indicators, providing information about the extent of potential drivers of drug resistance at the ART site. In 2009, 41.9% of sites did notachieve the WHO target of 100% appropriate first-line prescriptions; 6.3% still experienced high rates (> 20%) of loss to follow-up, and 16.2% had low retention of patients (< 70%) on first-line prescriptions in the first year of treatment. Stock-outs of antiretroviral drugs occurred at 22.7% of sites. Haiti, Guyana, and the Mesoamerican region are planning and implementing WHO HIVDR monitoring surveys or threshold surveys. New HIVDR surveillance tools for concentrated epidemics would promote further scale-up. Extending the WHO HIVDR lab network in Latin America is key to strengthening regional lab capacity to support quality assuredHIVDR surveillance. The WHO HIVDR control strategy is feasible and can be rolled out in LAC. Integrating HIVDR activities in national HIV care and treatment plans is key to ensuring the sustainability of this strategy.
Hacia fines del 2010, América Latina y el Caribe lograron una cobertura de tratamiento antirretroviral de 63%. Se recomienda la ejecución de medidas para controlar la farmacorresistencia del VIH a nivel de país para potenciar al máximo la eficacia y la sostenibilidad de los programas de tratamiento antirretroviral. Desde el 2006, la Organización Panamericana de la Salud ha apoyado la aplicación de la estrategia de la Organización Mundial de la Salud (OMS) para la prevención y la evaluación de la farmacorresistenciadel VIH mediante actividades regionales de formación de capacidad y de cooperación técnica directa en 30 países de América Latina y el Caribe. En 2010, 85 centros en 19 países notificaron indicadores de alerta temprana y suministraron información acerca del alcance de los posibles impulsores de la farmacorresistencia enlos centros de tratamiento antirretroviral. En el 2009, 41,9% de los centros no lograron la meta de la OMS de 100% de prescripción de medicamentos de primera línea apropiados; 6,3% todavía tenían tasas elevadas (> 20%) de pérdida de seguimiento y 16,2% tenían una baja retención de pacientes (< 70%) en tratamiento con antirretrovirales deprimera línea en el primer año de tratamiento. Se registraron desabastecimientos de medicamentos antirretrovirales en 22,7% de los centros. Haiti, Guyana y la zona mesoamericana están planificando y ejecutando estudios de vigilancia de la farmacorresistencia del VIH o estudios del umbral de la OMS. Las nuevas herramientas para la vigilancia de la farmacorresistencia del VIH en las epidemias concentradas permitiránuna mejor vigilancia. La ampliación de la red de laboratorios de farmacorresistenciadel VIH acreditados por la OMS en América Latina es fundamental para el fortalecimientode la capacidad de los laboratorios regionales, a fin de de efectuar una vigilancia de la farmacorresistencia del VIH de calidad garantizada...
Assuntos
Humanos , HIV-1 , Fármacos Anti-HIV/farmacologia , Farmacorresistência Viral , Vigilância da População , Organização Mundial da Saúde/organização & administração , Fármacos Anti-HIV/provisão & distribuição , Região do Caribe/epidemiologia , Farmacorresistência Viral/genética , Estudos de Viabilidade , Infecções por HIV/epidemiologia , Infecções por HIV/virologia , Implementação de Plano de Saúde , Inquéritos Epidemiológicos , América Latina/epidemiologia , Fatores de Tempo , Saúde GlobalRESUMO
By the end of 2010, Latin America and the Caribbean (LAC) achieved 63% antiretroviral treatment (ART) coverage. Measures to control HIV drug resistance (HIVDR) at the country level are recommended to maximize the efficacy and sustainability of ART programs. Since 2006, the Pan American Health Organization has supported implementation of the World Health Organization (WHO) strategy for HIVDR prevention and assessment through regional capacity-building activities and direct technical cooperation in 30 LAC countries. By 2010, 85 sites in 19 countries reported early warning indicators, providing information about the extent of potential drivers of drug resistance at the ART site. In 2009, 41.9% of sites did not achieve the WHO target of 100% appropriate first-line prescriptions; 6.3% still experienced high rates (> 20%) of loss to follow-up, and 16.2% had low retention of patients (< 70%) on first-line prescriptions in the first year of treatment. Stock-outs of antiretroviral drugs occurred at 22.7% of sites. Haiti, Guyana, and the Mesoamerican region are planning and implementing WHO HIVDR monitoring surveys or threshold surveys. New HIVDR surveillance tools for concentrated epidemics would promote further scale-up. Extending the WHO HIVDR lab network in Latin America is key to strengthening regional lab capacity to support quality assured HIVDR surveillance. The WHO HIVDR control strategy is feasible and can be rolled out in LAC. Integrating HIVDR activities in national HIV care and treatment plans is key to ensuring the sustainability of this strategy.